| Literature DB >> 34830314 |
Shingo Urate1, Hiromichi Wakui1, Kengo Azushima1, Takahiro Yamaji2, Toru Suzuki1, Eriko Abe1, Shohei Tanaka1, Shinya Taguchi1, Shunichiro Tsukamoto1, Sho Kinguchi1, Kazushi Uneda1, Tomohiko Kanaoka1, Yoshitoshi Atobe3, Kengo Funakoshi3, Akio Yamashita4, Kouichi Tamura1.
Abstract
The kidney is one of the most susceptible organs to age-related impairments. Generally, renal aging is accompanied by renal fibrosis, which is the final common pathway of chronic kidney diseases. Aristolochic acid (AA), a nephrotoxic agent, causes AA nephropathy (AAN), which is characterized by progressive renal fibrosis and functional decline. Although renal fibrosis is associated with renal aging, whether AA induces renal aging remains unclear. The aim of the present study is to investigate the potential use of AAN as a model of renal aging. Here, we examined senescence-related factors in AAN models by chronically administering AA to C57BL/6 mice. Compared with controls, the AA group demonstrated aging kidney phenotypes, such as renal atrophy, renal functional decline, and tubulointerstitial fibrosis. Additionally, AA promoted cellular senescence specifically in the kidneys, and increased renal p16 mRNA expression and senescence-associated β-galactosidase activity. Furthermore, AA-treated mice exhibited proximal tubular mitochondrial abnormalities, as well as reactive oxygen species accumulation. Klotho, an antiaging gene, was also significantly decreased in the kidneys of AA-treated mice. Collectively, the results of the present study indicate that AA alters senescence-related factors, and that renal fibrosis is closely related to renal aging.Entities:
Keywords: aging; aristolochic acid; cellular senescence; chronic kidney disease; renal fibrosis
Mesh:
Substances:
Year: 2021 PMID: 34830314 PMCID: PMC8618437 DOI: 10.3390/ijms222212432
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Effects of AA treatment on BW, systolic BP, heart rate, tissue weight, and renal function. (A) BW changes in the vehicle-control and AA groups. (B) Systolic BP and (C) heart rate in the vehicle-control and AA groups at 0, 4, and 8 weeks after the initiation of AA treatment. (D) Heart weight/BW and (E) kidney weight/BW ratios in the vehicle-control and AA groups at 8 weeks after the initiation of AA treatment. (F) Plasma creatinine level, (G) plasma UN level, and (H) creatinine clearance were measured in the vehicle-control and AA groups at 8 weeks after the initiation of AA treatment. (A–C) * p < 0.05 compared with the vehicle-control group. Data are presented as mean ± standard error of the mean (SEM) (n = 5 per group) and analyzed using two-way ANOVA with Bonferroni’s post-hoc test. (D–H) * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the vehicle-control group. Data are presented as mean ± SEM (n = 4–5 per group) and were analyzed using the unpaired Student’s t-test. AA: aristolochic acid; BP: blood pressure; BW: body weight; UN: urea nitrogen.
Figure 2Effects of AA treatment on renal pathological alterations assessed by histological examination and fibrosis-related gene expression. (A) Representative images of PAS-stained kidney sections (bar: 50 µm) and the glomerular area in the vehicle-control and AA groups. (B) Representative images of MT-stained kidney sections in the vehicle-control and AA groups (bar: 50 µm). Relative renal mRNA expression of (C) collagen I, (D) collagen III, and (E) TGF-β in the vehicle-control and AA groups. (A,C–E) * p < 0.05, *** p < 0.001 compared with the vehicle-control group. Data are presented as mean ± SEM (n = 4–5 per group) and were analyzed using the unpaired Student’s t-test. AA: aristolochic acid; MT: Masson’s trichrome; PAS: periodic acid-Schiff; TGF-β: transforming growth factor-β.
Figure 3Effects of AA treatment on proximal tubular cells and ROS. Relative renal mRNA expression of (A) p53, (B) p21, (C) p16, and (D) GLS. (E) Representative images of SA-β-gal-stained kidney sections in the vehicle-control and AA groups (bar: 100 µm). (F) Representative TEM images of the proximal tubular cells in the vehicle-control and AA groups (original magnification: ×5000; bar: 1 μm). Relative renal mRNA expression of (G) Bnip3 and (H) Nox2 in the vehicle-control and AA groups. (I) Relative renal 4-HNE level in the vehicle-control and AA groups. (A–D,G–I) * p < 0.05, ** p < 0.01, *** p < 0.001 compared with the vehicle-control group. Data are presented as mean ± SEM (n = 5 per group) and were analyzed using the unpaired Student’s t-test. 4-HNE: 4-hydroxy-2-nonenal; AA: aristolochic acid; Bnip3: BCL2/adenovirus E1B 19-kDa interacting protein 3; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GLS: glutaminase; NS: nonspecific band; SA-β-gal: senescence-associated β-galactosidase; TEM: transmission electron microscope.
Figure 4Effects of AA treatment on the renal expression of antiaging proteins. (A–C) Relative renal protein expression of Klotho, NAMPT, and SIRT1 in the vehicle-control and AA groups. *** p < 0.001 compared with the vehicle-control group. Data are presented as mean ± SEM (n = 5 per group) and were analyzed using the unpaired Student’s t-test. AA: aristolochic acid; GAPDH: glyceraldehyde-3-phosphate dehydrogenase, NAMPT: nicotinamide phosphoribosyltransferase; NS: nonspecific band; SIRT1: sirtuin1.